Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025MedicineOpen Access

Mendelian randomization reveals causal circulatory microRNAs in prostate cancer pathogenesis and prognosis

View Full Paper
Ask AI
Bookmark
Share

Authors

ZCZhicheng CongDQDandan QiuHHHai‐Ping Hu

Discussion

Loading...

Member takes

Overview

Mendelian randomization reveals five protective microRNAs in prostate cancer, suggesting new biomarkers and therapeutic targets.

Key Points

  • Five microRNAs showed an inverse association with prostate cancer risk, indicating potential protective factors.
  • Using Mendelian randomization, the study validated two microRNAs with a significant odds ratio for prostate cancer.
  • Survival analysis highlighted nine genes linked to microRNAs that are enriched in critical pathways relevant to cancer.
  • The identified microRNAs could serve as noninvasive biomarkers for prostate cancer diagnosis and treatment options.

Cite This Study

Cong et al. (2025) studied this question.

synapsesocial.com/papers/68c1a8f654b1d3bfb60e19a5https://doi.org/10.1097/md.0000000000043613
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Identification of putative causal associations between MicroRNAs and breast cancer via Mendelian randomization and bioinformatic analysis2026 · 1 citations
  2. 2Systematic characterization of cross-source miRNA biomarkers in prostate cancer with computational-experimental integrated analysis2025
  3. 3In silico Identification of microRNAs Differentially Expressed in Prostate Cancer and Related to Tumor Aggressiveness2026 · 2 citations
  4. 4MicroRNAs in Prostate Cancer Liquid Biopsies: Early Detection, Prognosis, and Treatment Monitoring2026 · 7 citations
  5. 5Abstract 7584: Tumor microRNA expressions associated with prostate cancer aggressiveness across independent cohorts.2026